• KOL
    • Bipolar Disorder
    • Joseph R Calabrese
    • Joseph R Calabrese: Influence Statistics

      Joseph R Calabrese

      Joseph R Calabrese

      Show email address

      Gao, MD, PhD, Calabrese, MD, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Case Western Reserve University School of Medicine, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Joseph R Calabrese:Expert Impact

      Concepts for whichJoseph R Calabresehas direct influence:Bipolar disorder,Bipolar depression,Patients bipolar disorder,Suicidal ideation,Bipolar disorders,Rapid cycling,National guard,Major depression.

      Joseph R Calabrese:KOL impact

      Concepts related to the work of other authors for whichfor which Joseph R Calabrese has influence:Bipolar disorder,Depressive symptoms,Major depression,Mental health,Mood stabilizers,Suicidal ideation,Atypical antipsychotics.

      KOL Resume for Joseph R Calabrese

      Year
      2022

      Gao, MD, PhD, Calabrese, MD, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Case Western Reserve University School of Medicine, Cleveland, Ohio. Ayati, PhD, Department of Computer Science, University of Texas Rio Grande Valley, Edinburg, TX. Koyuturk, PhD, Department of Computer and Data Sciences, Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, OH. Ganocy, PhD, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Lazarus, MD, Case Western Reserve University School of Medicine, Cleveland, Ohio; CellPrint Biotechnology, Cleveland, Ohio; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Kaye PhD, Christian, PhD, Kaplan, MD, PhD, CellPrint Biotechnology, Cleveland, Ohio.

      Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA

      2021

      Department of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

      Case Western Reserve University School of Medicine, Cleveland, OH, United States

      2020

      Mood Disorders Program, Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, USA.

      Department of Psychiatry, Case Western Reserve University, Cleveland OH, USA

      University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH.

      2019

      Case Western Reserve University, Cleveland, Ohio.

      Adult Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

      University Hospitals, Department of Psychiatry, Cleveland, OH USA

      2018

      Department of Psychiatry, Mood Disorders Program, University Hospitals Cleveland Medical Center/Case Western Reserve University, 10524 Euclid Avenue, 12th Floor, Cleveland, OH, 44106, United States. Electronic address:

      Mood and Anxiety Clinic, The Mood Disorders Program, Case Western Reserve University School of Medicine, Cleveland, OH, USA

      2017

      Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio.

      University Hospitals Case Medical Center, 10524 Euclid Ave, Cleveland, OH 44106.

      UH Case Medical Center, Psychiatry, Cleveland, USA

      2016

      Mood and Anxiety Clinic in the Mood Disorders Program of University Hospitals Case Medical Center/Case Western University School of Medicine, 10524 Euclid Avenue, 12th floor, 44106, Cleveland, OH, USA

      Joseph R. Calabrese, MD, Department of Psychiatry, Case Western Reserve University.

      Department of Psychiatry, Case Western University, Cleveland, OH, United States

      Bipolar Disorders Research Center, Cleveland, Ohio

      2015

      Department of Psychiatry, Case Western Reserve University School of Medicine and Mood Disorders Program, University Hospitals Case Medical Center, Cleveland, Ohio, USA

      From Forest Research Institute, Jersey City, N.J.; Gedeon Richter, Budapest; Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; University Hospitals Case Medical Center, Case Western Reserve School of Medicine, Cleveland; and University of British Columbia, Vancouver.

      2014

      Department of Psychiatry, University Hospital Case Medical Center, Case Western Reserve University, Cleveland, OH, USA

      10524 Euclid Ave, Room 12-135, Cleveland, OH 44106

      Case Western Reserve University School of Medicine, United States

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Joseph R Calabrese is among the top experts in the world.
      Concept World rank
      casi correlation #1
      disorder rcbd #1
      size efficacy measures #1
      male periodicity recurrence #1
      quetiapinexr alcohol #1
      time depressive #1
      lithium therapy noncompliance #1
      dvpx antipsychotic agents #1
      42 day patients #1
      placebo bipolar #1
      mania manic syndrome #1
      lithium versus divalproex #1
      adverse events 7 #1
      somnolence sedation #1
      lamotrigine trials lamotrigine #1
      nnth #1
      lamotrigine acute treatment #1
      lamotrigine aed #1
      disorder maintenance #1
      acute response divalproex #1
      3 samples samples #1
      somnolence quetiapinexr #1
      teaes novo #1
      antimanic response lithium #1
      bipolar disorder growing #1
      newonset akathisia #1
      release monotherapy patients #1
      nnth ziprasidone #1
      creb rats rats #1
      bipolar youths #1
      symptomatic relapse patients #1
      wg mania study #1
      pymrs adolescent ymrs #1
      somnolence lower dose #1
      pfc activity subjects #1
      newonset akathisia teaes #1
      awg bpd #1
      thiazoles animals bpid #1
      agomelatine adjunctive therapy #1
      madrs studies #1
      qtp monotherapy #1
      quetiapine acute treatment #1
      sadness depressive severity #1
      study 100 meq #1
      cbz div #1
      rcbpdii counterparts #1
      ads rcbdii #1
      payers psychiatry #1
      mania discontinuation #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Joseph R Calabrese

      KOL-Index: 22219

      OBJECTIVE: To estimate the number needed to treat to harm (NNTH) for discontinuation due to adverse events with atypical antipsychotics relative to placebo during the treatment of bipolar depression, major depressive disorder (MDD), and generalized anxiety disorder (GAD).

      DATA SOURCES: English-language literature published and cited in MEDLINE from January 1966 to May 2009 was searched with the terms antipsychotic, atypical antipsychotic, generic and brand names of atypical ...

      Known for Bipolar Depression | Atypical Antipsychotics | Major Depressive Disorder | Mdd Gad | Discontinuation Adverse Events
      KOL-Index: 17049

      The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, ...

      Known for Bipolar Disorder | Canadian Network | 2018 Guidelines | Lithium Quetiapine | Anxiety Treatments
      KOL-Index: 16863

      BACKGROUND: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder.

      METHODS: After an 8- to 16-week open-label phase during which treatment ...

      Known for Lamotrigine Lithium | Bipolar Disorder | Placebo Time | Mood Episodes | Relapse Recurrence
      KOL-Index: 15561

      This study evaluated the efficacy and tolerability of quetiapine monotherapy for depressive episodes in patients with bipolar I or II disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) who were randomized to 8 weeks of double-blind treatment with quetiapine (300 or 600 mg/d; once daily, evening dosing) or placebo. Patients were assessed weekly using the Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAM-D). The ...

      Known for Quetiapine Monotherapy | Placebo Week | Mental Disorders | Depressive Episodes | Improvements Baseline
      KOL-Index: 15143

      OBJECTIVE: To assess whether combination treatment with lithium and divalproex is more effective than lithium monotherapy in prolonging the time to mood episode recurrence in patients with rapid-cycling bipolar disorder and comorbid substance abuse and/or dependence.

      METHOD: A 6-month, double-blind, parallel-group comparison was carried out in patients who met DSM-IV criteria for (1) bipolar I or II disorder; (2) alcohol, cannabis, or cocaine abuse within the last 3 months or dependence ...

      Known for Lithium Monotherapy | Cycling Bipolar | Substance Abuse | Combination Treatment | Episode Recurrence
      KOL-Index: 15095

      The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence and is designed to be used in conjunction with the previous publications. The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate, and several atypical antipsychotics continue to be ...

      Known for Bipolar Disorder | Canadian Network | Canmat Guidelines | Collaborative Update | Acute Mania
      KOL-Index: 15022

      OBJECTIVE Few studies have been reported that support the efficacy of adjunctive therapy for patients with bipolar I depression who have had an insufficient response to monotherapy with mood-stabilizing agents. The authors investigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression. METHOD Patients were randomly assigned to receive 6 weeks of double-blind adjunctive treatment with ...

      Known for Adjunctive Therapy | Treatment Lurasidone | Bipolar Depression | Lithium Valproate | Week Placebo
      KOL-Index: 14821

      BACKGROUND: Bipolar disorder is a serious and common psychiatric disorder characterized by manic and depressive mood switches and a relapsing and remitting course. The cornerstone of clinical management is stabilization and prophylaxis using mood-stabilizing medications to reduce both manic and depressive symptoms. Lithium remains the gold standard of treatment with the strongest data for both efficacy and suicide prevention. However, many patients do not respond to this medication, and ...

      Known for Lithium Response | Bipolar Disorder | Genome Wide | Valproic Acid | Retrospective Studies
      KOL-Index: 14745

      OBJECTIVE: The authors evaluated the efficacy, safety, and tolerability of cariprazine, an atypical antipsychotic candidate, in adult patients with acute bipolar I depression.

      METHOD: This was an 8-week multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with bipolar I disorder experiencing a current major depressive episode. Patients were randomly assigned (1:1:1:1) to receive placebo or cariprazine at 0.75, 1.5, ...

      Known for Cariprazine Placebo | 30 Day | Efficacy Safety | Baseline Week | Patients Bipolar
      KOL-Index: 14222

      OBJECTIVE: Bipolar disorder is highly comorbid with substance use disorders, and this comorbidity may be associated with a more severe course of illness, but the impact of comorbid substance abuse on recovery from major depressive episodes in these patients has not been adequately examined. The authors hypothesized that comorbid drug and alcohol use disorders would be associated with longer time to recovery in patients with bipolar disorder.

      METHOD: Subjects (N=3,750) with bipolar I or ...

      Known for Bipolar Disorder | Time Recovery | Systematic Treatment | Enhancement Program | Substance Comorbidity

      Key People For Bipolar Disorder

      Top KOLs in the world
      #1
      Eduardo Eduard
      bipolar disorder cognitive impairment acute mania
      #2
      Robert M Post
      bipolar disorder affective illness depressed patients
      #3
      Susan L McElroy
      bipolar disorder binge eating bulimia nervosa
      #4
      Paul E Keck
      bipolar disorder acute mania united states
      #5
      Joseph R Calabrese
      bipolar disorder suicidal ideation rapid cycling
      #6
      Gary S Sachs
      bipolar disorder rapid cycling acute mania

      Gao, MD, PhD, Calabrese, MD, Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Case Western Reserve University School of Medicine, Cleveland, Ohio. Ayati, PhD, Department of Computer Science, University of Texa

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.